CD1D and neoplasm: In the absence of PBMCs, twice-weekly i.p. treatment with CD1d-Vδ2 hu-bsTCE (2 mg kg−1) did not inhibit tumor growth, whereas admixed PBMCs (in absence of bsTCE) slightly reduced tumor growth (Figures 6C and S5C).